ABSTRACT In the present study, the pathogenicity of fowl adenovirus (FAdV) serotype 4 strain HB1501 was systematically determined by using different doses and routes of inoculation in chickens and assessed the immune efficacy induced by fowl adenovirus serotype 4 (FAdV-4) strain SB15 in a vaccination trial. The results revealed that strain HB1501 was highly virulent in chickens, inflicting 30 to 100% mortality when administered by intramuscular and intravenous routes, and its pathogenicity was influenced markedly by the inoculation route. The inactivated oil-emulsion FAdV-4 vaccine derived from strain SB15 completely protected specific pathogen-free chickens against morbidity and mortality following infection with the virulent FAdV-4 strain HB1501. Importantly, no obvious clinical signs or gross lesions were observed and high antibody levels against FAdV were measured in the SB15-vaccinated chickens, indicating the potential of this strain to become an alternative vaccine candidate. This study provides detailed information on the pathogenicity of FAdV-4, which should be of great value to the control of hepatitis-hydropericardium syndrome.
INTRODUCTION
Hepatitis-hydropericardium syndrome (HHS) was first identified in Pakistan in 1987 (Anjum et al., 1989) . As a severe disease in poultry, it is caused mainly by fowl adenovirus serotype 4 (FAdV-4), which is characterized by the accumulation of transparent or strawcolored fluid with aqueous or gelatinous consistency in the pericardial sac, nephritis and hepatitis, and has a high mortality rate usually ranging from 30 to 70% (Kim et al., 2008; Schachner et al., 2014) .
Fowl adenoviruses (FAdV) belong to the Aviadenovirus genus, which together with 4 other genera (Mastadenovirus, Atadenovirus, Siadenovirus, and Ichtadenovirus) are Adenoviridae family members. Fowl adenoviruses have been classified into 5 species (A to E) and further divided into 12 serotypes (FAdV 1 to 8a, and 8b to 11) (Hess, 2000) . Besides HHS, FAdV causes a variety of diseases, such as inclusion body hepatitis and adenoviral gizzard erosion. Each of the 12 FAdV serotypes is associated with inclusion body hepatitis, but some FAdV-1 strains are responsible for adenoviral gizzard erosion (Ono et al., 2003) .
Fowl adenoviruses have been reported in many countries, such as the USA (Mendelson et al., 1995) , Canada (Grgić et al., 2014; Schachner et al., 2014) , Korea (Park et al., 2017) , Poland (Niczyporuk, 2016) , Japan (Mase et al., 2009) , India (Singh et al., 2002) , and Chile (Toro et al., 1999) , and they have a severe economic impact on the global poultry industry. Furthermore, the number of HHS cases has increased since 2013 in China (Zhao et al., 2015) , and the FAdV-4 strains have been mainly Chinese isolates (Li et al., 2016; Ye et al., 2016) . Various vaccines such as inactivated liver homogenate, live or inactivated oil-emulsion vaccines, and new generation vaccines have been developed to control HHS in some countries (Afzal and Ahmad, 1990; Toro et al., 2002; Kim et al., 2014; Schachner et al., 2014) , and these vaccines are efficient in protecting birds from FAdV-4.
Two FAdV strains, SB15 and HB1501, were isolated from different flocks during HHS outbreaks in China in 2015. Both of them belong to FAdV-4 with a close genetic relationship. Here, the pathogenicity of HB1501 was systematically determined by inoculating chickens with this virus using different doses and inoculation routes. In the vaccination trial, the immune efficacy induced by strain SB15, which was plaque-purified 3 times in the chicken hepatocellular carcinoma cell line (LMH) and inactivated with formaldehyde, was assessed by challenging birds with the virulent HB1501 strain, and then evaluating them by clinical 2647 observation, clinical sign scores, gross autopsy, and serological methodologies.
MATERIALS AND METHODS

Animals and ethics statement
Specific pathogen-free (SPF) white leghorn chickens were obtained from the Beijing Merial Vital Laboratory Animal Technology Co., Ltd, China. All the chickens were kept in isolators throughout the experiment at China Agricultural University. The experimental protocols and the housing facility were approved by the Animal Welfare and Ethical Censor Committee at China Agricultural University and Beijing Administration Committee of Laboratory Animals under the leadership of the Beijing Association for Science and Technology. The approval ID is XYXK (Jing) 2013-0013.
Cells and Viruses
The LMH cells were grown in Dulbecco's Modified Eagle's Medium/F12 (DMEM/F12) (ThermoFischer, NY, USA) containing 10% fetal bovine serum (FBS) (ThermoFischer) and 1% penicillinstreptomycin (Macgene, Beijing, China) at 37
• C with 5% CO 2 . FAdV-4 SB15 and HB1501 strains were isolated from the liver samples of suspected FAdV-infected chickens collected in 2015. The highly virulent HB1501 isolate was used as the challenge strain to determine the immune efficacy induced by the inactivated FAdV SB15 vaccine. Two FAdV strains were cultured in LMH cells. The 2 strains were plaque-purified three times as described previously (Alexander et al., 1998) and then titrated by median tissue culture infective doses (TCID 50 ) and plaque-forming units (PFU). The TCID 50 was determined in 96-well titration plates, according to the endpoint method of Reed and Muench (1938) . PFU was determined as described previously (Alexander et al., 1998) .
Cytopathic Effects (CPE) of FAdV in LMH Cells
The chicken hepatocellular cells in 24-well plates were infected with SB15 or HB1501 at 10 6.0 TCID 50 , and then incubated in DMEM/F12 containing 1% FBS. The CPE of each FAdV strain in LMH cells was observed at 12 h intervals until 48 h post-infection (hpi). Uninfected cells served as the control.
Optimal Harvest Time Determination
The growth dynamics of the FAdV-4 strain SB15 was evaluated in LMH cells to determine the optimal harvest time. Cells in triplicate wells of 24-well plates were infected with the SB15 strain containing 10 6.0 TCID 50 , and then incubated in DMEM/F12 containing 1% FBS. The cells and culture supernatants were harvested at 8 h intervals until 64 hpi. The viral titers were quantified in LMH cells and expressed as TCID 50 .
Pathogenicity Testing of FAdV-4 HB1501 in SPF Chickens
Grouping and Viral Challenge One hundred 3-wkold SPF chickens were randomly divided into 10 groups of 10 each and housed separately in isolators. Birds were inoculated with 0.2 mL of FAdV-4 HB1501 using different doses (10 7.0 TCID 50 /bird, 10 6.0 TCID 50 /bird, and 10 5.0 TCID 50 /bird) and routes of inoculation (oral; intramuscular, I.M.; intravenous, I.V.) except for the control group (group 10) ( Table 1) .
Clinical Observations and Sampling All the birds were monitored daily for clinical signs (e.g., depression, ruffled feathers, reluctance to move) or death for 14 d. The clinical signs were assessed as daily clinical scores: 0 for normal, 1 for mild depression, 2 for severe depression, 3 for paralysis/prostration, and 4 for death (Zhao et al., 2015) . Serum samples were collected at 21 d post-inoculation (dpi) and antibody levels against FAdV-4 were determined by a recombinant fiber-2 protein-based indirect enzyme-linked immunesorbent antibody assay (ELISA), whose cut-off value was 0.130 (OD 450nm value). The optimal dilution level of the serum or secondary antibodies were 1:200 and 1:6,000, respectively. All the birds were then humanely euthanized and necropsied.
Immune Efficacy Trial of FAdV strain SB15
Oil-Adjuvant Inactivated FAdV Vaccine Preparation The LMH-derived SB15 virus was inactivated with formaldehyde at 4
• C at a final concentration of 0.1% for 24 h. Inactivated viral antigen was mixed with the oil emulsion adjuvant, Marcol 52 (Seppic, Paris, France), at a ratio of 1:1 (V/V).
Chicken Immunizations Forty 1-wk-old SPF chickens were randomly divided into 4 groups of 10 each and housed separately in isolators. Two groups of chickens were inoculated subcutaneously with the SB15 vaccine at a dose of 10 6.5 TCID 50 /bird or 10 7.5 TCID 50 /bird. Another 20 birds served as the unvaccinated control group (Table 2) . To confirm the antibody responses against the inactivated FAdV-4 vaccine, sera from the vaccinated chickens were collected at 21 dpi and the antibody levels were determined by ELISA.
Challenge Tests The birds were challenged with 0.2 mL (10 6.0 TCID 50 /bird) of FAdV-4 HB1501 via the intravenous route at 21 dpi (Table 2 ). All the birds were monitored daily and scored for clinical signs for 14 d. The clinical signs were scored as previously described. Serum samples were collected on d 14 post challenge and antibody levels were determined by ELISA. All birds were euthanized and necropsied on d 14 post challenge. 
RESULTS
Cytopathic Effects of FAdV in LMH Cells
LMH cells are normally polygonal with a dendriticlike appearance. Uninfected cells served as the control and no CPE was observed with them. In cells infected with both FAdV strains, a visible CPE was observed at 24 hpi, as characterized by cell rounding and cell aggregation. When the incubation time was increased, the spacing between the cells widened and particles were observed in the cells at high magnification (400×). At 36 hpi, there was a severe CPE, and complete detachment of the cell monolayer was observed at 48 hpi.
Virus Purification and Titration
The 2 FAdV strains used in our study were plaquepurified 3 times and titrated by TCID 50 and PFU. Both strains produced visible plaques 4 d after inoculation, which developed progressively to diameters of 1 to 3 mm within 8 dpi. The number of plaques decreased as the dilution increased. The TCID 50 for HB1501 and SB15 were 10 8.0 TCID 50 /0.2 mL and 10
TCID 50 /0.2 mL, respectively. The PFU calculation for SB15 was 2.06 × 10 8.0 PFU/mL. 
Optimal Harvest Time Determination
The growth dynamics of SB15 were evaluated in LMH cells at 8 h intervals until 64 hpi to determine the optimal harvest time. The values obtained represent averages of the results from 3 independent experiments (Figure 1) . The virus titer showed an increasing trend, reached a maximum at 48 hpi, gradually declining thereafter. The optimal harvest time for maximizing the virus yield was determined at 32 to 48 hpi.
Pathogenicity Testing of FAdV-4 HB1501 in SPF Chickens
Clinical Signs No clinical signs or deaths were observed in the oral infection and control groups during the experiment. Chickens inoculated with HB1501 by the I.M. and I.V. route showed obvious clinical signs of depression, and also ruffled feathers, decreased feeding and water consumption, reluctance to move, paralysis, and death ( Figure 2A) .
In group 4 (I.M., 10 7.0 TCID 50 /bird), the first clinical signs of the disease were observed at 2 dpi. Mortality started at 3 dpi, and at 5 dpi all the animals were found dead ( Figure 2B ). The mortality rate was 100%. In group 5 (I.M., 10 6.0 TCID 50 /bird), the first clinical signs of the disease were observed at 3 dpi. Mortality started at 3 dpi, 8 birds died in all, and the mortality rate reached 80%. The surviving birds gradually recovered from 6 dpi. In group 6 (I.M., 10 5.0 TCID 50 /bird), the first clinical signs of the disease were observed at 3 dpi. Mortality started at 4 dpi, 7 birds died in all, and the mortality rate was 70%. The surviving birds gradually recovered from 10 dpi. Similar results were found in the I.V. groups. Mortality was observed between 2 and 7 dpi, when 10, 10, and 3 birds from groups 7, 8, and 9 died, respectively. The mortality rates for groups 7, 8, and 9 reached 100, 100, and 30%, respectively.
Gross Lesions Obvious lesions were observed in all the dead birds at necropsy, including hydropericardium, swollen and friable liver with multi focal areas of necrosis and petechial hemorrhage, and swollen and pale kidneys. No obvious lesions were observed in the oral infection groups or in any birds that recovered from infection with HB1501. No gross lesions were identified in any control group birds.
Antibody Responses Sera were collected at 21 dpi from all the surviving chickens and tested by ELISA. Most of the birds inoculated with HB1501 showed pos- itive antibody responses, regardless of the infection routes and doses (Figure 3) . In groups 1, 2, and 3, the antibody response against FAdV was detected in most of the surviving birds, with positivity rates of 90, 50, and 90%, respectively. In groups 5 and 6, the antibody response against FAdV was detected in all the surviving birds, with positivity rates of 100 and 100%, respectively. In group 7, the antibody response against FAdV was detected in all the surviving birds, with a positivity rate of 100%. Chickens infected by the I.V. route had higher titers than those in the other groups. The antibody response against FAdV was not detected in any control group birds.
Immune Efficacy Trial of FAdV SB15
Clinical Signs No clinical signs or deaths attributable to FAdV-4 were identified in any birds in the control group or the SB15-vaccinated groups during the experiment. Birds in the unvaccinated group challenged with strain HB1501 showed clinical signs of depression, ruffled feathers, and reluctance to move as early as 2 dpi, ( Figure 4A ). The mean scores per group per day for the clinical signs in the challenge group were much higher than those of the vaccination groups and the control group. Mortality was observed between 3 and 5 dpi, when 6 birds died, and the mortality rate reached 60% ( Figure 4B ). The surviving birds gradually recovered from 7 dpi.
Gross Lesions No gross lesions were identified in any control group birds or the SB15 vaccinated groups during the experiment. Obvious lesions were observed in all the dead birds in the unvaccinated group challenged with HB1501, including hydropericardium, swollen and friable liver with multifocal areas of necrosis and petechial hemorrhage, and swollen and pale kidneys. These results suggest that both vaccination doses (10 7.5 TCID 50 /bird, 10 6.5 TCID 50 /bird) provided complete protection against HB1501.
Antibody Response Sera were collected at 21 dpi and 14 d post-challenge (dpc) and tested by ELISA ( Figure 4C ). All birds inoculated with SB15 showed positive antibody responses at 21 dpi. Birds vaccinated with higher doses of the virus had higher titers than those in the low dose group. The mean ELISA titers for birds in the vaccination groups that received 10 7.5 TCID 50 /bird or 10 6.5 TCID 50 /bird were 1.14 and 0.57 at 21 dpi, respectively. Furthermore, the values increased to 1.31 and 1.33 at 14 dpc, respectively. The mean ELISA titer for the surviving birds in the unvaccinated challenge group was 1.28. Antibody responses against FAdV were not detected in any control group birds.
DISCUSSION
Hepatitis-hydropericardium syndrome, the most severe disease induced by FAdV infection, has significant economic impact on the global poultry industry (Toro et al., 1999; Singh et al., 2002; Mase et al., 2009; Grgić et al., 2014; Schachner et al., 2014; Niczyporuk, 2016; Park et al., 2017) . Various vaccines have been made to control HHS (Afzal and Ahmad, 1990; Toro et al., 2002; Kim et al., 2014; Schachner et al., 2014) . Two FAdV-4 strains, SB15 and HB1501, were isolated from HHS-affected flocks during FAdV outbreaks in China in 2015. Here, the pathogenecity of HB1501 was systematically determined by different doses and routes of inoculation in chickens. We then further assessed the immune efficacy of SB15 with a challenge-protection study.
LMH is a continuous cell line appropriate for the growth of FAdV (Alexander et al., 1998) , and is more convenient for research than primary chicken embryo liver cells and chick kidney cells, as they are fairly tedious to prepare. Therefore, the two FAdV strains used in this study were adapted to growth in LMH cells. With both strains, visible CPE characterized by cell rounding and cell aggregation was observed. Granules were observed in the cells at high magnification (400×), which is consistent with the description for primary chick kidney cell and primary chicken embryo liver cell cultures (Adair et al., 1979; Li et al., 2016) . Our results support many others detailing that most FAdV strains can be propagated efficiently in LMH cells (Alexander et al., 1998; Grgić et al., 2011) .
The pathogenicity of the FAdV-4 HB1501 was systematically determined using different doses and routes of inoculation. These data revealed that HB1501 was highly virulent in SPF chickens infected by I.M. and I.V. routes, inflicting 30-100% mortality. Obvious clinical signs and gross lesions were observed, and those caused by HB1501 were identical to those described in previous studies of pathogenicity for an isolate of FAdV-4 (Zhao et al., 2015; Niu et al., 2016) . It should be noted that the pathogenicity of HB1501 was markedly influenced by the route of inoculation. When the virus was inoculated orally, which is the natural route for infection with FAdV, HB1501 did not display pathogenicity, and no obvious clinical signs, deaths, or gross lesions were observed; however, it was highly virulent when inoculated by the I.M. and I.V. routes. Similar results were observed in several previous studies on FAdV-4 pathogenicity (Reece et al., 1987; Ojkic and Nagy, 2003) . Additionally, we showed that increasing the dose of the virus accelerated the disease course and severity. The mortality rate also gradually increased, reaching 100% when the injection dose was higher than 10 7.0 TCID 50 by the I.M. route or 10 6.0 TCID 50 by the I.V. route. To the best of our knowledge, this is the first study to systematically compare the influence of three different routes (oral, I.M. and I.V.) and doses of inoculation on the pathogenicity of a strain of FAdV.
To confirm that the infection was effectively established, serum samples were collected for detection of FAdV antibodies during pathogenicity testing of HB1501. Our results showed that most of the birds inoculated with HB1501 tested positive for FAdV antibodies at 21 dpi, except for a small number of chickens inoculated by the oral route. It was found that chickens infected by the I.V. route had higher ELISA titers than those in the other groups in the pathogenicity test of strain HB1501, which was identical to those described in previous studies (Schonewille et al., 2010; Grgić et al., 2011) . The reason might be that natural route of viral infection may be unable to ensure that all birds receive the same amount of virus (Grgić et al., 2011) . In this study, the I.V. route (10 6.0 TCID 50 /bird) was chosen for challenge infections with strain HB1501 in the immune efficacy trial, and the results were consistent with a study on the evaluation of protection efficacy induced by an inactivated oil-emulsion FAdV-4 vaccine (Kim et al., 2014) .
Many studies have been conducted with the aim of protecting birds from infection with FAdV-4 in some countries (Mansoor et al., 2011; Kim et al., 2014) . Broiler chickens free from maternal antibodies against FAdV were immunized with a chicken embryo-adapted FAdV-4 isolate, which was attenuated by serially passaging, and the vaccination gave 94.73% protection (Mansoor et al., 2011) . A vaccine containing inactivated oil-emulsion FAdV-4 was shown to provide broad crossprotection against various FAdV serotypes (Kim et al., 2014) . In this study, the immune efficacy of SB15 was assessed using a challenge-protection approach. Our results suggest that SB15 completely protected SPF birds against morbidity and mortality when challenged with the virulent FAdV-4 HB1501 strain via the I.V. route. Neither clinical signs nor gross lesions at necropsy were observed and the antibody levels of the vaccinated chickens were high. These results indicate that this strain can be used in vaccination procedures to reduce the economic losses caused by FAdV-4 infections.
The mechanism of FAdV infection is very complex in chickens (Li et al., 2016) . It has been suggested that there is a synergism between FAdV and chicken infectious anemia virus or other viruses (Toro et al., 2000) . Therefore, besides preventing FAdV infections, vaccination and good animal management practices for the control of infectious immunosuppressive agents such as infectious bursal disease virus and chicken infectious anemia virus are necessary (Shivachandra et al., 2003; Balamurugan amd Kataria, 2006) .
In conclusion, our data confirm that FAdV-4 HB1501 is highly virulent in chickens and its pathogenicity was markedly influenced by the route of inoculation. FAdV-4 SB15 provided effective protection against challenge with HB1501, indicating its potential as an alternative vaccine candidate for controlling FAdV-4 infections and HHS in China.
